GLPwatch
Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes
NCT03297879 · Completed
Last updated 2026-05-28This clinical trial compares the effects of exenatide and metformin on blood sugar control in overweight or obese adults who have just been diagnosed with type 2 diabetes.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) treatment study
Participants 230 people
Who can join Ages 20–65 · all sexes
Timeline Started 2013-01 · est. completion 2016-02
What this study is testing ClinicalTrials.gov NCT03297879 ↗
Description as written by the study sponsor.
The present study assessed the therapeutic effect of exenatide and metformin as the initial therapy in overweight/obese patients with newly diagnosed Type 2 diabetes (T2D).
Treatments tested
- Exenatide or metformin hydrochloride Drug
Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
| Main thing measured | The change of HbA1c |
|---|---|
| Sponsor | Beijing Chao Yang Hospital |
| Conditions studied | Type2 Diabetes |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03297879 ↗